Literature DB >> 7948558

Fluoroquinolone use and fluoroquinolone resistance: is there an association?

P Richard1, M H Delangle, D Merrien, S Barillé, A Reynaud, C Minozzi, H Richet.   

Abstract

In an assessment of potential risk factors for nosocomial infections caused by fluoroquinolone-resistant gram-negative organisms, 68 patients who developed a nosocomial infection caused by a fluoroquinolone-resistant gram-negative bacillus were compared with 191 patients who developed a nosocomial infection caused by a fluoroquinolone-susceptible gram-negative bacillus. A history of previous infection, immunosuppression, prior receipt of fluoroquinolones, and hospitalization on the burn unit were independent risk factors. Except for immunosuppression, the same risk factors were identified when the 50 patients whose isolates were resistant to fluoroquinolones, aminoglycosides, and beta-lactam antibiotics were compared with the 95 patients whose isolates were susceptible to all of these classes of antimicrobial agents. The identification of hospitalization on the burn unit as a risk factor was attributable to an outbreak of infections caused by a resistant strain of Pseudomonas aeruginosa during the study period. The occurrence of nosocomial outbreaks and the selective pressure of fluoroquinolone use were the main exogenous risk factors involved in the emergence of resistance to fluoroquinolones.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7948558     DOI: 10.1093/clinids/19.1.54

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  18 in total

1.  Posttreatment changes in Escherichia coli antimicrobial susceptibility rates among diarrheic patients treated with ciprofloxacin.

Authors:  Shannon D Putnam; John W Sanders; David R Tribble; David R Rockabrand; Mark S Riddle; Patrick J Rozmajzl; Robert W Frenck
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

2.  Impact of a fluoroquinolone formulary change on acquisition of quinolone-resistant gram-negative bacilli.

Authors:  B N Hota; S Pur; L Phillips; R A Weinstein; J Segreti
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-06       Impact factor: 3.267

Review 3.  Epidemiological interpretation of studies examining the effect of antibiotic usage on resistance.

Authors:  Vered Schechner; Elizabeth Temkin; Stephan Harbarth; Yehuda Carmeli; Mitchell J Schwaber
Journal:  Clin Microbiol Rev       Date:  2013-04       Impact factor: 26.132

4.  Characterization of clinical isolates of Escherichia coli showing high levels of fluoroquinolone resistance.

Authors:  N Lehn; J Stower-Hoffmann; T Kott; C Strassner; H Wagner; M Kronke; W Schneider-Brachert
Journal:  J Clin Microbiol       Date:  1996-03       Impact factor: 5.948

5.  Fluoroquinolone resistance patterns after formulary addition of ofloxacin. A clinical isolate study.

Authors:  G E Stein
Journal:  Drugs       Date:  1995       Impact factor: 9.546

6.  Effect of quinolone use on antimicrobial susceptibility patterns over a 5-year period.

Authors:  J Segreti; R Connelly
Journal:  Drugs       Date:  1995       Impact factor: 9.546

7.  Pharmacokinetic profiles of high-dose intravenous ciprofloxacin in severe sepsis. The Baragwanath Ciprofloxacin Study Group.

Authors:  J Lipman; J Scribante; A G Gous; H Hon; S Tshukutsoane
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

8.  Nosocomial acquisition of Pseudomonas aeruginosa resistant to both ciprofloxacin and imipenem: a risk factor and laboratory analysis.

Authors:  M R Mueller; M K Hayden; S K Fridkin; D K Warren; L Phillips; K Lolans; J P Quinn
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-02-26       Impact factor: 3.267

9.  Molecular epidemiology of fluoroquinolone-resistant Escherichia coli bloodstream isolates from patients admitted to European cancer centers.

Authors:  M Oethinger; S Conrad; K Kaifel; A Cometta; J Bille; G Klotz; M P Glauser; R Marre; W V Kern
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

Review 10.  Prophylactic use of the new quinolones for prevention of nosocomial infection in the intensive care unit.

Authors:  P D Potgieter; J M Hammond
Journal:  Drugs       Date:  1995       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.